Last reviewed · How we verify
Anti Thymocyte Globulin
Anti Thymocyte Globulin (ATG), marketed by Novartis Pharmaceuticals, is a well-established therapy for the prophylaxis and treatment of acute rejection in kidney transplant patients. A key strength of ATG is its proven efficacy and safety profile, supported by its current market position and ongoing use in clinical practice. The primary risk to ATG's market position is the expiration of its key composition patent in 2028, which could lead to increased competition from generic alternatives.
At a glance
| Generic name | Anti Thymocyte Globulin |
|---|---|
| Also known as | Thymoglobulin, ATG |
| Sponsor | Novartis Pharmaceuticals |
| Drug class | Immunoglobulin G [EPC] |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
- Prophylaxis and treatment of acute rejection in kidney transplant
Common side effects
- Urinary tract infection
- Abdominal pain
- Hypertension
- Nausea
- Shortness of breath
- Fever
- Headache
- Anxiety
- Chills
- Increased potassium levels
- Low platelet counts
- Low white blood cell counts
Serious adverse events
- Severe infections
- Malignancies
- Anaphylactic shock
- Serum sickness
- Myocardial infarction
- Pulmonary edema
- Severe urinary tract infection
- CMV infection
- Epstein-Barr virus-induced lymphoma
- Decreased blood pressure
Drug interactions
- rabbit immune globulins
Key clinical trials
- A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation (PHASE2, PHASE3)
- Upfront Autologous HSCT Versus Immunosuppression in Early Diffuse Cutaneous Systemic Sclerosis (PHASE4)
- Allogeneic Hematopoietic Stem Cell Transplant for GATA2 Mutations (PHASE2)
- Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients (PHASE2)
- Ruxolitinib-Decitabine Intensified Conditioning Regimen for AML: A Randomized Trial (PHASE4)
- Study on the Efficacy and Safety of the TmBU Conditioning Regimen in High-risk or Relapsed/Refractory Acute Leukemia (PHASE2)
- Allogeneic Hematopoietic Cell Transplantation for Disorders of T-cell Proliferation and/or Dysregulation (PHASE2)
- A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New Onset Type 1 Diabetes (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Anti Thymocyte Globulin CI brief — competitive landscape report
- Anti Thymocyte Globulin updates RSS · CI watch RSS
- Novartis Pharmaceuticals portfolio CI